FOLD Valuation

Amicus Therapeutics Inc

Add to Watchlist

Advanced Chart

7.600

+0.2(2.703%)1D

Overview
Forecast
Valuation
Earnings

FOLD Relative Valuation

FOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FOLD is overvalued; if below, it's undervalued.

Historical Valuation

Amicus Therapeutics Inc (FOLD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.27 is considered Undervalued compared with the five-year average of -0.04. The fair price of Amicus Therapeutics Inc (FOLD) is between 13.07 to 25.73 according to relative valuation methord. Compared to the current price of 7.60 USD , Amicus Therapeutics Inc is Undervalued By 41.84%.

Relative Value

Fair Zone

13.07-25.73

Current Price：7.60

41.84%

Undervalued

42.12

Trailing

Forward

22.08

EV/EBITDA

Amicus Therapeutics Inc. (FOLD) has a current EV/EBITDA of 22.08. The 5-year average EV/EBITDA is 37.52. The thresholds are as follows: Strongly Undervalued below -255.97, Undervalued between -255.97 and -109.22, Fairly Valued between 184.27 and -109.22, Overvalued between 184.27 and 331.02, and Strongly Overvalued above 331.02. The current Forward EV/EBITDA of 22.08 falls within the Historic Trend Line -Fairly Valued range.

21.27

EV/EBIT

Amicus Therapeutics Inc. (FOLD) has a current EV/EBIT of 21.27. The 5-year average EV/EBIT is -125.02. The thresholds are as follows: Strongly Undervalued below -1359.66, Undervalued between -1359.66 and -742.34, Fairly Valued between 492.30 and -742.34, Overvalued between 492.30 and 1109.62, and Strongly Overvalued above 1109.62. The current Forward EV/EBIT of 21.27 falls within the Historic Trend Line -Fairly Valued range.

3.27

Amicus Therapeutics Inc. (FOLD) has a current PS of 3.27. The 5-year average PS is 7.78. The thresholds are as follows: Strongly Undervalued below 0.97, Undervalued between 0.97 and 4.37, Fairly Valued between 11.18 and 4.37, Overvalued between 11.18 and 14.59, and Strongly Overvalued above 14.59. The current Forward PS of 3.27 falls within the Undervalued range.

7.08

P/OCF

Amicus Therapeutics Inc. (FOLD) has a current P/OCF of 7.08. The 5-year average P/OCF is 1639.14. The thresholds are as follows: Strongly Undervalued below -11771.03, Undervalued between -11771.03 and -5065.95, Fairly Valued between 8344.22 and -5065.95, Overvalued between 8344.22 and 15049.31, and Strongly Overvalued above 15049.31. The current Forward P/OCF of 7.08 falls within the Historic Trend Line -Fairly Valued range.

12.31

P/FCF

Amicus Therapeutics Inc. (FOLD) has a current P/FCF of 12.31. The 5-year average P/FCF is -34.79. The thresholds are as follows: Strongly Undervalued below -278.02, Undervalued between -278.02 and -156.40, Fairly Valued between 86.82 and -156.40, Overvalued between 86.82 and 208.43, and Strongly Overvalued above 208.43. The current Forward P/FCF of 12.31 falls within the Historic Trend Line -Fairly Valued range.

Amicus Therapeutics Inc (FOLD) has a current Price-to-Book (P/B) ratio of 11.16. Compared to its 3-year average P/B ratio of 22.69 , the current P/B ratio is approximately -50.83% higher. Relative to its 5-year average P/B ratio of 18.35, the current P/B ratio is about -39.18% higher. Amicus Therapeutics Inc (FOLD) has a Forward Free Cash Flow (FCF) yield of approximately -2.16%. Compared to its 3-year average FCF yield of -2.94%, the current FCF yield is approximately -26.59% lower. Relative to its 5-year average FCF yield of -4.55% , the current FCF yield is about -52.50% lower.

11.16

P/B

Median3y

22.69

Median5y

18.35

-2.16

FCF Yield

Median3y

-2.94

Median5y

-4.55

Competitors Valuation Multiple

The average P/S ratio for FOLD's competitors is 9.25, providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD) exhibits a P/S ratio of 3.27, which is -64.62% above the industry average. Given its robust revenue growth of 22.12%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FOLD.O

Amicus Therapeutics Inc

Tarsus Pharmaceuticals Inc

Ocular Therapeutix Inc

Supernus Pharmaceuticals Inc

3.12

-1.71%

2.43B

Performance Decomposition

Market capitalization of FOLD decreased by 34.54% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -12.39 to -15.79.

The secondary factor is the Revenue Growth, contributed 22.12%to the performance.

Overall, the performance of FOLD in the past 1 year is driven by Margin Expansion. Which is more sustainable.

22.12%

126.67M → 154.69M

Revenue Growth

27.44%

-12.39 → -15.79

Margin Expansion

-84.10%

-374.69 → -59.58

P/E Change

-34.54%